TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS Stock
Certificat
DE000SN0QXX2
| Delayed Deutsche Boerse AG 10:33:37 2024-07-17 am EDT | ||
| 2.01 EUR | -2.43% |
|
| Current month | +6.74% | ||
| 1 month | +0.98% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 2.01 | -2.43% |
| 24-07-16 | 2.06 | -0.96% |
| 24-07-15 | 2.08 | +0.97% |
| 24-07-12 | 2.06 | -0.96% |
| 24-07-11 | 2.08 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update July 17, 2024 at 10:33 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SN0QXX |
| ISIN | DE000SN0QXX2 |
| Date issued | 2022-05-09 |
| Strike | 268.5 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.39 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.11 € |
|---|---|
| Lowest since issue | 0.15 € |
| Spread | 0.01 € |
| Spread % | 0.51% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
489
USD
Average target price
473.5
USD
Spread / Average Target
-3.17%
- Stock Market
- Certificates
- Certificat
